You have a lot to protect, bank more than cord blood.

Our Scientific Expertise is Second to None

LifebankUSA: Technological Leaders Caring for Your Future

As the only company that offers cord blood, placenta blood and tissue banking - and the first-and the first to release placenta-derived stem cells for a successful transplant - we are proud to be technological leaders in a field that is helping so many families and is poised to help countless others.

We enable you to bank more of the stem cells (called CD34+ stem cells) shown to increase transplant success and survival,1 and more mesenchymal* - like cells, which may prove to be useful in the emerging field of regenerative medicine.2-5 Our strict procedures deliver unsurpassed purity,† 6(see below) and you can trust that the stem cells your family banks will be available when you need them most. And you can be secure in the knowledge that our parent company, Celgene Corporation, provides the resources we need to keep doing what we do best: preserving stem cells for generations to come.

A Commitment to Purity

While all cord blood contains red blood cells, these cells have no therapeutic benefit and can actually lead to complications if not removed. LifebankUSA removes red blood cells through a process called "red blood cell depletion" to ensure that cord blood units are, on average, 99% pure.6 Unlike LifebankUSA, some other cord blood banks have purity levels as low as 71%.7,8 This means that their units contain more red blood cells that may cause complications if the cord blood units are used for treatment.

The LifebankUSA optimal red blood cell removal process eliminates the need for additional preparation at the time of transplant if your baby's stem cells are ever needed. This is important because further manipulation may lower the number of cells available for use.

*Mesenchymal is pronounced muh-ZINK-i-mul.
†Purity is defined as the absence of red blood cells.

Please click here for more opinions from leading transplant surgeons and obstetricians.

Stem cells from placental and cord blood are indicated to rebuild blood. View Product Information

References:
  1. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umblical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611-1618
  2. Harris DT. Non-haematological uses of cord blood stem cells. Br J Haematol. 2009;147(2):177-184.
  3. Richardson SM, Hoyland JA, Mobasheri R, Csaki C, Shakibaei M, Mobasheri A. Mesenchymal stem cells in regenerative medicine: opportunitiesand challenges for articular cartilage and intervertebral disc tissue engineering. J Cell Physiol. 2010;222(1):23-32
  4. Yen BL, Huang H-I, Chien C-C, et al. Isolation of multipotent cells from human term placenta. Stem Cells. 2005;23(1):3-9.
  5. Styczynski J, Cheung Y-K, Garvin J, et al. Unrelated donor transplants: outcomes of unerlated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2005;34(2):129-136.
  6. Data on file, LifebankUSA; 2010;
  7. Dobrila L, Chapman J, Marr D, Kumar V, Coelho P, Rubinstein P. ThermoGenesis AXP AutoXpress platform and BioArchive system for automated cord blood banking.
  8. Evaluation of Processing Technologies for Umbilical Cord Blood; Henderson, Christianna; et al. Saint Louis Cord Blood Bank, SSM Cardinal Glennon Children's Medical Center http://www.slcbb.org/PDFs/Evaluation%20of%20ProcessingTechnologies%20for%20UCB.pdf . Accessed Nov 14, 2011